RAD-150 TLB-150 research capsules contain TLB-150 benzoate, an ester derivative of RAD-140 with molecular formula C27H20ClN5O3 and molecular weight near 497.9. The benzoic acid group is attached to the RAD-140 scaffold, a modification intended to alter chemical stability and release behaviour relative to the parent molecule.
Specification Table
TLB-150 benzoate and parent compound data
| Property |
Value |
| Compound |
TLB-150 benzoate |
| Common name |
RAD-150 |
| CAS number |
1208070-53-4 |
| Molecular formula |
C27H20ClN5O3 |
| Molecular weight |
Approximately 497.9 g/mol |
| Chemical relationship |
Benzoate ester of RAD-140 |
| Parent compound |
RAD-140 (testolone) |
| CAS, RAD-140 |
1182367-47-0 |
| Molecular formula, RAD-140 |
C20H16ClN5O2 |
| Molecular weight, RAD-140 |
393.83 g/mol |
| Originating organisation, RAD-140 |
Radius Health |
| Molecular target |
Androgen receptor (AR, NR3C4), via the parent compound |
| Peer-reviewed studies of TLB-150 |
None identified in indexed databases |
| Human pharmacokinetic data |
None published |
| Animal pharmacokinetic data |
None published |
| Capsule strength |
5 mg |
| Appearance |
White to off-white powder within a gelatin capsule shell |
| Purity |
Per lot-specific certificate of analysis |
| Solubility |
Soluble in DMSO. Poorly soluble in water |
| Storage |
Room temperature, sealed, protected from light and moisture |
| Regulatory status |
No approved human or veterinary formulation in any jurisdiction |
Are There Clinical Trials on TLB-150?
No. Search queries reaching this page carry the compound name in quotation marks, paired with clinical trial, study and human study, which tells you people are hunting specifically for primary evidence. They deserve a direct answer rather than a page that talks around it.
A search of indexed biomedical databases returns no peer-reviewed study of TLB-150 benzoate. No clinical trial. No animal pharmacokinetic paper. No published receptor characterisation of the ester itself. The compound exists in supplier catalogues and in analytical reference standards, and essentially nowhere in the scientific literature.
That absence is unusual even by research-chemical standards. Andarine has a multi-paper academic record. AC-262,536 has a primary pharmacology paper. GW-501516 accumulated a two-year rodent carcinogenicity dataset. TLB-150 has none of that.
A researcher choosing this compound is working with a molecule whose properties are inferred from its parent rather than measured directly. That is a legitimate position for some experimental questions. It is not a position anyone should occupy without knowing they are in it.
What Is Known About the Parent Compound?
RAD-140, developed at Radius Health, is a non-steroidal androgen receptor ligand with formula C20H16ClN5O2 and molecular weight 393.83. Unlike TLB-150 it has a genuine published record, including receptor characterisation and preclinical work.
RAD-140 was investigated for androgen receptor-dependent indications and reached early clinical evaluation. Published preclinical work describes activity in androgen-responsive tissue alongside a selectivity profile that separates it from steroidal androgens. That framing is standard for the class.
Everything the specification table above says about a molecular target derives from RAD-140 rather than from TLB-150. The ester is presumed to release the parent compound on hydrolysis, so the receptor pharmacology is presumed to be the parent’s. That presumption is chemically reasonable and experimentally unverified for this specific ester.
What Does the Benzoate Ester Change, and What Is Assumed?
Esterification is a well-established formulation strategy. Attaching a carboxylic acid to a hydroxyl group produces a molecule with different solubility, different chemical stability and, when a suitable esterase is present, gradual hydrolysis back to the parent compound. Steroid chemistry has used the approach for decades.
Applied here, the benzoate group raises molecular weight from 393.83 to roughly 497.9, a 26 percent increase. On a mass-equivalent basis, therefore, a given weight of TLB-150 contains meaningfully fewer molecules of releasable parent compound than the same weight of RAD-140. Five milligrams of TLB-150 is approximately 10 micromoles against approximately 12.7 micromoles for the same mass of RAD-140.
What is assumed rather than demonstrated is the hydrolysis behaviour. The rate depends on which esterases are present in a given system, at what concentration, and with what affinity for this particular substrate. Those parameters have not been published for TLB-150. In a cell culture system with limited esterase activity, the ester may not hydrolyse appreciably at all, in which case the preparation is not delivering RAD-140 in any meaningful quantity.
That is a testable question and a reasonable experiment. It is not a settled fact.
How Should RAD-150 TLB-150 Research Be Designed Around These Gaps?
First, verify hydrolysis analytically in the system actually being used, rather than assuming that it happens at all. A simple analytical time course, measuring parent compound appearance in the relevant matrix, converts the central assumption into a measurement. Without it, every downstream interpretation rests on an unverified premise.
Second, include RAD-140 itself as a comparator wherever the design allows. If the ester is functioning as intended, the two should converge on similar receptor-level readings once hydrolysis has occurred, with the ester lagging. Divergence indicates something more interesting is happening, and either way the comparison is informative.
Third, normalise by moles and account for the mass difference described above. A comparison run on milligram equivalence carries a 26 percent systematic bias before anything else is considered.
Fourth, document all of it in more detail than the work seems to warrant. On a compound with no published literature, internal records are the only evidence base that will exist.
How Would You Verify What Is Actually in the Capsule?
With no published characterisation of this compound, analytical verification carries more weight in RAD-150 TLB-150 research than anywhere else in this catalogue. There is no literature to fall back on if the material is not what the label says.
Liquid chromatography with mass spectrometric detection is the starting point. The ester and its parent differ by 104 mass units, corresponding to the benzoyl group, so distinguishing them is straightforward once both are resolved chromatographically. A sample containing substantial free RAD-140 alongside the ester indicates hydrolysis during synthesis or storage rather than a pure preparation.
That distinction is worth making before any experiment, not after. Because the ester is presumed to hydrolyse to the parent anyway, a preparation that has already partly hydrolysed will behave differently from a fresh one in ways that no visual inspection reveals and no label discloses.
Nuclear magnetic resonance confirms structure where mass spectrometry only confirms mass. For a compound with no published spectra, that means comparing against predicted shifts rather than a reference spectrum, which is less definitive but still catches gross structural errors.
None of this is unusual analytical work. It is only unusual to need it this badly, and that follows directly from the absence of any published record.
Why Ester Prodrugs Are Used at All
Knowing the general strategy makes it easier to separate what is plausible here from what is merely assumed.
Esterification addresses specific formulation problems. It can improve solubility in a chosen vehicle, protect a reactive hydroxyl group during storage, slow release from a depot, or alter absorption across a membrane. Steroid chemistry has used the approach for decades, and testosterone esters are the familiar example.
The strategy works when the ester is cleaved reliably by esterases present where the compound needs to act. That reliability is the whole basis of the design, and it varies enormously between esters. Some hydrolyse within minutes of entering plasma. Others are stable enough to pass through unchanged.
Nobody has published which of those behaviours applies to a benzoate ester sitting on this particular scaffold. Benzoate esters are generally more resistant to hydrolysis than short-chain aliphatic esters such as acetate or propionate, which suggests slower release rather than faster, but suggests is the operative word. Nobody has measured it for this molecule.
Handling and Storage in Laboratory Practice
Supplied as 5 mg capsules. Weigh contents for analytical work rather than relying on nominal fill.
Esters are susceptible to hydrolysis under humid conditions and at raised pH, which is a storage consideration rather than only a biological one. Keep the material dry and sealed. A preparation that has partially hydrolysed in storage contains a mixture of ester and parent compound in unknown proportion, and nothing about its appearance will indicate that.
DMSO is the standard stock solvent given poor aqueous solubility. Prepare stocks fresh where the design permits, and avoid holding the compound in aqueous buffer for extended periods before use. Record lot number, solvent, concentration, preparation date, and where relevant the interval between preparation and use.
Published Literature
The reference list below covers the parent compound and the general ester-prodrug approach. There is no entry for TLB-150 itself because no peer-reviewed study of it was identified.
- Miller CP, Shomali M, Lyttle CR, O’Dea LS, Herendeen H, Gallacher K, Paquin D, Compton DR, Sahoo B, Kerrigan SA, Burge MS, Nickels M, Green JL, Katzenellenbogen JA, Tchesnokov A, Hattersley G. ACS Medicinal Chemistry Letters. 2011;2(2):124-129.
- Jayaraman A, Christensen A, Moser VA, Vest RS, Miller CP, Hattersley G, Pike CJ. Endocrinology. 2014;155(4):1398-1406.
- Narayanan R, Coss CC, Dalton JT. Molecular and Cellular Endocrinology. 2018;465:134-142.
- Rautio J, Kumpulainen H, Järvinen T, Savolainen J. Nature Reviews Drug Discovery. 2008;7(3):255-270.
Frequently Asked Questions
Are there clinical trials on TLB-150?
No, and this is the most important thing on the page, because search queries arriving here carry the compound name in quotation marks alongside the words clinical trial and human study. A search of indexed biomedical databases returns nothing. No trial, no animal pharmacokinetic paper, no published receptor characterisation of the ester.
What is RAD-150 TLB-150 research material?
Capsules containing TLB-150 benzoate, the benzoate ester of RAD-140, with molecular formula C27H20ClN5O3, molecular weight near 497.9 and CAS number 1208070-53-4. Supplied at 5 mg per capsule. It is for laboratory research use only and is not approved for human or veterinary use anywhere.
How does RAD-150 differ from RAD-140?
RAD-150 is RAD-140 carrying a benzoic acid group attached as an ester, which raises molecular weight from 393.83 to roughly 497.9 and changes both solubility and chemical stability in the process. The ester is presumed to hydrolyse back to the parent. That behaviour has never been published for this compound.
Does the ester actually release RAD-140?
That is assumed rather than demonstrated, and the assumption carries more weight in this case than anyone reading a product listing would guess. Hydrolysis rate depends on which esterases are present and at what concentration. In a system with limited esterase activity, little parent compound may be released at all.
Why does the molecular weight difference matter?
The benzoate group adds 26 percent to molecular weight, so 5 mg of TLB-150 amounts to roughly 10 micromoles while the same mass of RAD-140 amounts to roughly 12.7, which builds a systematic bias into any comparison run on milligram equivalence. Normalise by moles. The correction is trivial and routinely skipped.
What research is published on RAD-140?
RAD-140 has a genuine record including receptor characterisation and preclinical work from Radius Health and academic collaborators, and it reached early clinical evaluation for androgen receptor-dependent indications. Everything the specification table says about a molecular target derives from that work. None of it derives from measuring the ester.
How should experiments account for the missing data?
Verify hydrolysis analytically in the specific system rather than assuming it occurs, include RAD-140 as a comparator wherever the design permits, normalise by moles rather than mass, and document far more thoroughly than the work appears to warrant. The internal record is the only evidence base. Nothing published will corroborate it.
Does the ester affect storage requirements?
Yes, and more than for the parent compound, because esters hydrolyse under humid conditions and at raised pH, meaning material can degrade in storage without any visible sign that it has. Keep it dry and sealed. A partially hydrolysed preparation contains both species in unknown proportion.
Is TLB-150 the same as RAD-150?
They refer to the same compound, though TLB-150 is the designation more likely to return anything at all in a chemical database search while RAD-150 is the marketplace name reflecting the relationship to RAD-140. Neither returns peer-reviewed studies. That is because none exist.
How would you verify capsule contents?
Liquid chromatography with mass spectrometric detection, since the ester and its parent differ by exactly 104 mass units corresponding to the benzoyl group, which makes them straightforward to tell apart once both are chromatographically resolved. Substantial free RAD-140 indicates hydrolysis. That happens during synthesis or storage, not in the vial by design.
Why does verification matter more for this compound?
Because RAD-150 TLB-150 research has no published characterisation to fall back on when something looks wrong, and for compounds with a literature an anomalous finding can at least be checked against prior work. Here there is no prior work. Internal analytical data is the only evidence the material is what the label claims.
Are benzoate esters fast or slow to hydrolyse?
Generally slower to hydrolyse than short-chain aliphatic esters such as acetate or propionate, which points toward gradual release rather than rapid conversion, though the inference rests on general ester chemistry rather than on any measurement. Nobody has measured it here. The distinction between suggests and shows matters.
What does a mass difference of 104 units indicate?
It indicates the benzoyl group, which is exactly what separates TLB-150 from RAD-140 and makes the two straightforward to distinguish by mass spectrometry once chromatography has resolved them. A sample showing substantial free parent alongside the ester has hydrolysed. That points to synthesis or storage rather than a clean preparation.
Compliance Statement
RAD-150 TLB-150 research capsules is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use, no peer-reviewed study of this compound has been published, and androgen receptor ligands are prohibited in competitive sport under World Anti-Doping Agency rules. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
15 reviews for RAD-150 (TLB-150) 5mg Capsules